A commitment to ensuring that our medicines are available to those who need them most is just as important as our commitment to developing innovative treatments. The patient assistance programs of our U.S. subsidiaries Daiichi Sankyo, Inc. (DSI) and American Regent, Inc., make it possible for tens of thousands of patients in the United States to use the Company’s pharmaceuticals.
The Daiichi Sankyo Open Care Program provides free products to those who are prescribed DSI’s products and are under- or uninsured , as well as unable to identify alternative payment sources.
American Regent, Inc. also has a support program targeting some pharmaceuticals for patients who are either uninsured or lack sufficient coverage. Furthermore, DSI participates in Partnership for Prescription Assistance (PPA) program as a member of Pharmaceutical Research and Manufacturers of America. The PPA is a national coalition of pharmaceutical companies, doctors and other healthcare providers, patient advocates, and community groups etc. PPA helps patients identify potential assistance programs, assess potential eligibility, and support their enrollment.

Patient Assistance Programs